Teva Tops Valeant With $6.8B Cephalon Buy
Teva Pharmaceutical Industries Ltd. swooped in to buy Cephalon Inc. on Monday in a $6.8 billion deal that blew the doors off a previously rejected $5.7 billion bid by Valeant Pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article